BACKGROUND:Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. METHODS: We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receivedoxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was disease-free survival. Secondary end points were overall survival and safety. RESULTS: At a median follow-up of 65 months, 656 events triggered this protocol-specified analysis. The estimated disease-free survival rates at 5 years were 75% among patients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% among those receiving TCH. Estimated rates of overall survival were 87%, 92%, and 91%, respectively. No significant differences in efficacy (disease-free or overall survival) were found between the two trastuzumab regimens, whereas both were superior to AC-T. The rates of congestive heart failure and cardiac dysfunction were significantly higher in the group receiving AC-T plus trastuzumab than in the TCH group (P<0.001). Eight cases of acute leukemia were reported: seven in the groups receiving the anthracycline-based regimens and one in the TCH group subsequent to receiving an anthracycline outside the study. CONCLUSIONS: The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 ClinicalTrials.gov number, NCT00021255.).
RCT Entities:
BACKGROUND:Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. METHODS: We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was disease-free survival. Secondary end points were overall survival and safety. RESULTS: At a median follow-up of 65 months, 656 events triggered this protocol-specified analysis. The estimated disease-free survival rates at 5 years were 75% among patients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% among those receiving TCH. Estimated rates of overall survival were 87%, 92%, and 91%, respectively. No significant differences in efficacy (disease-free or overall survival) were found between the two trastuzumab regimens, whereas both were superior to AC-T. The rates of congestive heart failure and cardiac dysfunction were significantly higher in the group receiving AC-T plus trastuzumab than in the TCH group (P<0.001). Eight cases of acute leukemia were reported: seven in the groups receiving the anthracycline-based regimens and one in the TCH group subsequent to receiving an anthracycline outside the study. CONCLUSIONS: The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracyclineTCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 ClinicalTrials.gov number, NCT00021255.).
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: P Carter; L Presta; C M Gorman; J B Ridgway; D Henner; W L Wong; A M Rowland; C Kotts; M E Carver; H M Shepard Journal: Proc Natl Acad Sci U S A Date: 1992-05-15 Impact factor: 11.205
Authors: C C Benz; G K Scott; J C Sarup; R M Johnson; D Tripathy; E Coronado; H M Shepard; C K Osborne Journal: Breast Cancer Res Treat Date: 1992 Impact factor: 4.872
Authors: Mark D Pegram; Gottfried E Konecny; Carminda O'Callaghan; Malgorzata Beryt; Richard Pietras; Dennis J Slamon Journal: J Natl Cancer Inst Date: 2004-05-19 Impact factor: 13.506
Authors: Mark D Pegram; Tadeusz Pienkowski; Donald W Northfelt; Wolfgang Eiermann; Ravi Patel; Pierre Fumoleau; Eleonor Quan; John Crown; Deborah Toppmeyer; Michael Smylie; Alessandro Riva; Sandra Blitz; Michael F Press; David Reese; Mary-Ann Lindsay; Dennis J Slamon Journal: J Natl Cancer Inst Date: 2004-05-19 Impact factor: 13.506
Authors: H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos Journal: N Engl J Med Date: 1994-05-05 Impact factor: 91.245
Authors: Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland Journal: J Natl Compr Canc Netw Date: 2014-11 Impact factor: 11.908
Authors: Edith A Perez; Amylou C Dueck; Ann E McCullough; Monica M Reinholz; Kathleen S Tenner; Nancy E Davidson; Julie Gralow; Lyndsay N Harris; Leila A Kutteh; David W Hillman; Robert B Jenkins; Beiyun Chen Journal: J Natl Cancer Inst Date: 2011-12-02 Impact factor: 13.506
Authors: Sara A Hurvitz; David J Betting; Howard M Stern; Emmanuel Quinaux; Jeremy Stinson; Somasekar Seshagiri; Ying Zhao; Marc Buyse; John Mackey; Adrian Driga; Sambasivarao Damaraju; Mark X Sliwkowski; Nicholas J Robert; Vicente Valero; John Crown; Carla Falkson; Adam Brufsky; Tadeusz Pienkowski; Wolfgang Eiermann; Miguel Martin; Valerie Bee; Omkar Marathe; Dennis J Slamon; John M Timmerman Journal: Clin Cancer Res Date: 2012-04-13 Impact factor: 12.531
Authors: P Martín Martorell; B Bermejo de Las Heras; J A Pérez-Fidalgo; M Huerta Alvaro; M Martín; J Albanell; A Lluch Hernández Journal: Clin Transl Oncol Date: 2014-04-29 Impact factor: 3.405